The group’s principle activity is to develop drugs and therapies. The products of the group include Actos(R), Blopress(R) and Prevacid(R). The group’s therapies are used for metabolic diseases include diabetes, cancer and inflammatory conditions. The group operates from United States.
Executive Information
Name
Title
Email
Keith Wilson
Pres., Chief Scientific Officer
N/A
David Weitz
Sr. VP - US Intellectual Property Department, General Counsel
